Poster Session 1. Cancer Vaccines

​

P01.01.

Autologous live cell vaccination prolongs survival in immunotherapy-resistant glioma models

Giles D, Saint Louis, United States

 

P01.02.

Improving antitumor immunity through innate immune pathway modulation: Modified 3p-RNA shapes cytokine and cell death induction in human and murine models 

Teppert J, Munich , Germany

 

P01.03.

Improvement of HER2-targeted therapy by CD47-directed vaccination

Tobias J, Vienna, Austria

 

 

Poster Session 2. Cellular Therapies (including combinations)

 

P02.01.

Identification of T cell receptors targeting fusion-derived neoantigens in leukemia

Mazzotti L, Meldola, Italy

 

P02.02.

Identification of Tumor microenviornment-dependent resistance and emergence of persister cells to KRAS inhibition

Galban S, Ann Arbor, United States

 

P02.03.

Targeting CDCP1 With Single-domain Antibody-based CAR T Cells to Treat Solid Tumors

Schneppenheim F, Bonn, Germany

 

P02.04.

Composition Of Peripheral Blood Immune-Cells In Patients With Leukemia After Allogeneic Stem-Cell-Transplantation(Hsct) In Patients With Vs. Without Chronic(C) Or Acute(A) Graft-Versus-Host-Disease(Gvhd) And Healthy Donors

Simon V, Munich, Germany

 

P02.05.

Adaptive and Myeloid Dynamics After Allogeneic Stem Cell Transplantation in Acute or Chronic Graft-versus-Host Disease Undergoing Extracorporeal Photopheresis Versus Non–Graft-versus-Host Disease and Healthy Donors

Schreiner K, Munich, Germany

 

P02.06.

Reliable IFN-γ quantification for T cell functional analysis: analytical performance evaluation of a cytokine bead assay

Foerster-Marniok A, Bergisch Gladbach, Germany

 

P02.07.

Impact of human AB serum on CAR T cell manufacturing and metabolic properties of the drug product

Pitsch D, Bergisch Gladbach, Germany

 

P02.08.

Precise and flexible formulation and filling of CAR T cells in a fully closed and automated system – the new CliniMACS Prodigy TCTf process

Smorra D, Bergisch Gladbach, Germany

 

P02.09.

CSF1R⁺ myeloid cells mediate resistance to CAR-T-cell therapy in lung cancer brain metastases

Blobner J, Munich, Germany

 

P02.10.

Development of Nectin-2 specific Nano-CARs for the treatment of melanoma

Birr C, Bonn, Germany

 

P02.11.

Impact of systemic polychemotherapy in patients with pancreatic ductal adenocarcinoma on CAR T cell production and function

Michaelides S, Munich, Germany

 

P02.12.

Identification of an HLA-A*11:01-restricted KRASG12V-specific T cell receptor with strong antitumor responses in patient-derived cancer models

Palashati H, Oslo, Norway

 

P02.13.

Combination of adoptive cell therapy with ANV419, a selective IL-2Rβ/γ agonist, in patients with advanced melanoma

Lehmann J, Basel, Switzerland

 

P02.14.

Effects of Extracorporeal Photopheresis (ECP) on Leukemia-Specific and Anti-Leukemic Immune Cell Subsets in Leukemia Patients after Stem Cell Transplantation (HSCT) with acute or chronic Graft-versus-Host-Disease

Karatas C, Munich, Germany

 

P02.15.

Optimizing Lentiviral Vector Design and Production for Cell and Gene Therapies

Sadler B, London, United Kingdom

 

P02.16.

Cell avidity: the next-gen binding assay to advance immune-based therapeutic development

Moser J, Berlin, Germany

 

 

Poster Session 3. Immune Monitoring – Omics Technology

 

P03.01.

Immune monitoring of clinical T-cell responses in oncology immunotherapy using TCR sequencing and TCR-epitope annotation solutions

Bosschaerts T, Antwerp, Belgium

 

P03.02.

Decoding Single-Cell Protein Interactomes of CAR T cells with the Proximity Network Assay

Forster M, Stockholm, Sweden

 

P03.03.

Dried Antibody Cocktails: Setting the Benchmark for Fast and Robust Flow Cytometric Analysis in Cell and Gene Therapy

Schuster M, Bergisch Gladbach, Germany

 

 

Poster Session 4. Immunooncology in gynecological cancers

 

P04.01.

Reduced HLA diversity and impaired immune surveillance in very early-onset ovarian cancer patients

Soukupova J, Prague, Czech Republic

 

P04.02.

Membrane-Bound CX3CL1 Enhances NK Cell–Mediated Cytotoxicity in Ovarian Cancer

Biel R, Munich, Germany

 

 

Poster Session 5. Mode of action of Immune Therapies

 

P05.01.

Dynamic Modulation Of Natural Killer (Nk) And Cytokine Induced Killer (Cik) Cells By Extracorporeal Photopheresis In Chronic Graft-Versushost Disease After Hematopoetic Stem Cell Transplantation

Huang A, Freising, Germany

 

Poster Session 6. New Targets and New Leads

 

P06.01.

Spatial and single-cell profiling reveals stromal regulation of NK-cell cytotoxicity in gallbladder cancer

Kong L, Shanghai, China

 

P06.02.

β-adrenergic blockade unleashes cytotoxic CD4 T cell immunity in cancer

Madsen D, Herlev, Denmark

 

P06.03.

Next-Generation Targeted Immunomodulatory Protein for Human Prostate Cancer

Mascarelli D, Campinas, Brazil

 

P06.04.

Integrated de novo design and high-throughput screening of T cell receptor mimetic minibinders for multipronged intracellular cancer antigen targeting

Kempchen T, Bonn, Germany

 

P06.05.

De novo designed protein binders against cancer targets of the B7-H family

Broske B, Bonn, Germany

 

P06.06.

Clever-1 blockade as a potential immunomodulatory treatment for brain tumors.

Suresh R, Turku, Finland

 

P06.07.

Targeting immune checkpoint proteins CD47 and galectin-3 and -9 to improve macrophage mediated phagocytosis of pancreatic tumor cells

Stahmer L, Kiel, Germany

 

P06.08.

Targeting UXS1 to suppress colorectal cancer progression by regulating glycan biosynthesis, metabolic reprogramming, and immune evasion

Huang M, Taipei, Taiwan

 

P06.09.

Sequential photodynamic therapy and alphavirus-mediated interferon-γ delivery remodel the tumour microenvironment in breast cancer

Zajakina A, Riga, Latvia

 

P06.10.

Targeting GALE-mediated nucleotide sugar homeostasis suppresses breast cancer cell invasive behavior

Liao Y, Taipei, Taiwan

 

P06.11.

Exploration of the involvement of Receptor for Advanced Glycation End-products (RAGE) signaling in the regulation of tumor immunity by isoliquiritigenin in pancreatic cancer cells

Ko J, Hong Kong, China

 

P06.12.

PCIF1 correlates with immunosuppressive tumor microenvironment and predicts response to immune checkpoint blockade therapy in hepatocellular carcinoma

Wang Q, Fujian, China

 

P06.13.

Exploring epigenetic regulators of PD-L1 via CASPEX proximity labeling

Bursali B, Istanbul , Turkey

 

P06.14.

Reprogramming CAR-T cells to overcome tumor intrinsic resistance in solid tumors   

Mukherjee M, Regensburg , Germany

 

 

Poster Session 7. Polyspecific Antibody Derivatives

 

P07.01.

Targeting cancer antigens with de novo designed protein binders as bispecific T cell engagers

Tan E, Bonn, Germany

 

Poster Session 8. Tumor Immunology

 

P08.01.

Novel Anti-PD1 Predictive Signature and Functional Dendritic-Cell Biomarkers in Melanoma Identified with Systems Immunology

Koskela S, Turku, Finland

 

P08.02.

PD-L1 Blockade Primes Memory CD8⁺ T Cells with High Cytotoxic Potential for Lasting Antitumor Immunity

A. Soltan M, Kyoto, Japan

 

P08.03.

Drug Screening Reveals Epigenetic Regulators of PD-L1 Expression in Triple-Negative Breast Cancer

Bulut I, Istanbul, Turkey

 

P08.04.

Efficacy and Safety Analysis of Camrelizumab Combined with Chemotherapy in the Treatment of Advanced Pancreatic Cancer

Wang Y, Jinan, China

 

P08.05.

Developing an in vitro cutaneous melanoma skin model to study the response and resistance to immunotherapy

Demelas C, Lisboa, Portugal

 

P08.06.

NFDI4Immuno: A Federated FAIR Infrastructure to Accelerate Data Sharing in Cancer Immunotherapy

Eckert C, Berlin , Germany

 

P08.07.

Baseline immune determinants of response to neoadjuvant chemoradiotherapy plus durvalumab in esophageal adenocarcinoma: translational analyses from the phase II RICE trial

Garcia Marquez M, Cologne, Germany

 

P08.08.

Modulation of CD30 receptor shedding in the presence of EDTA on K562 cells pretreated with TNF

Jurisic V, Kragujevac, Serbia

 

P08.09.

A one-shot multiplex immunofluorescence platform for spatial analysis of heterogeneity in vascular immune niches in clear cell renal cell carcinoma

Kadzik S, Bonn, Germany

 

P08.10.

Pathological immune aggregates driven by HMGB1 limit antitumor immunity in esophageal squamous cell carcinoma

Kam N, Hong Kong, China

 

P08.11.

Integrative molecular and spatial analysis of endothelial cell heterogeneity in clear cell renal cell carcinoma

Kehl M, Bonn, Germany

 

P08.12.

TBX21 as a Transcription Factor Associated with Immunotherapy Response in Colorectal Cancer

Li T, Bochum, Germany

 

P08.13.

The mevalonate pathway fuels the immunogenic response to cancer in plasmacytoid dendritic cells.

Novoszel P, Vienna, Austria

 

P08.14.

Understanding time-resolved immune landscape to induct a combinatorial photothermal-immunotherapy approach for treatment of advanced-stage cancer

Rath S, Mumbai, India

 

P08.15.

Insect juvenile hormone III is a potential novel and highly efficient agent for immunotherapy of cancer

Sumbayev V, Didcot, United Kingdom

 

P08.16.

Enhancing the immunogenicity of esophagogastric adenocarcinoma by restoring antigen presentation and tumor-associated antigens using epigenetic drugs

Thelen M, Cologne, Germany

 

P08.17.

Pregnancy induced tissue-resident memory T cells protect against breast cancer

Vasanthakumar A, Melbourne, Australia

 

P08.18.

A single-cell and machine learning-derived prognostic signature of CD8⁺ exhausted T cells for colorectal cancer liver metastasis

Gao J, Shanghai, China

 

P08.19.

Application of SDC2 and Septin9 gene methylation detection in colorectal cancer diagnosis and immunotherapy efficacy assessment

Xie R, Shanghai, China

 

P08.20.

Heterogeneous long-term T cell fitness following CAR-T Therapy in DLBCL and multiple myeloma

Yao H, Erlangen, Germany

 

P08.21.

Immune environment of Prostate Cancer

Žvirblė M, Vilnius, Lithuania

  

Poster Session 9. Young Researcher Session

 

P09.01.

Blinatumumab resistance in paediatric relapsed acute lymphoblastic leukaemia is intrinsically driven byleukaemia aggressiveness especially resistance to apoptosis.

Alasfar L, Berlin, Germany

 

P09.02.

Oral administration of a TGF-β-enriched polymeric diet mitigates gastrointestinal acute GVHD

Chatterjee S, Freiburg, Germany

 

P09.03.

Role of SYK in reprogramming the LME and enhancing the susceptibility to CAR-T cell therapy

Dietz L, Cologne, Germany

 

P09.04.

Ablation of prostaglandin E2-signaling through dual receptor knock-out in CAR T cells enhances therapeutic efficacy in solid tumors

Dörr J, Munich, Germany

 

P09.05.

The effect of pancreatic enzyme replacement therapy on the gut microbiome and immune response of patients with pancreatic ductal adenocarcinoma associated pancreatic enzyme insufficiency

Fung K, Birmingham, United Kingdom

 

P09.06.

Metabolomic-Derived Biomarkers Predict Immunotherapy Efficacy in Advanced Non-small Cell Lung Cancer

Luo W, Guangzhou, China

 

P09.07.

Dual PTPN2/PTPN1 inhibition augments bispecific T cell engager activity in patient-derived tumor models

Rizk M, Vienna, Austria

 

P09.08.

The CD8+ T-cell response triggered by Nectin-4 and CD137 linked Bicyclic peptides

Smith G, Cambridge, United Kingdom

 

P09.09.

Adapter P329G-directed CAR T cells enable efficient targeting of lung cancer cells in living human lung slices

Menkhoff V, Munich, Germany

 

P09.10.

Competitive modulation of anti-P329G adapter CAR T cell activity using an untargeted CAR-adapter molecule

Stock S, Munich, Germany

 

P09.11.

LAMC2 Drives OSCC Progression by Regulating ERK/Akt-Mediated Cell Cycle Programs and Phenotypic Plasticity

Truong T, Ho Chi Minh City, Vietnam

 

P09.12.

Circulating inflammatory markers in endometrial cancer in survival predicition

Valiña Amado L, Santiago de Compostela, Spain

 

P09.13.

ARID1A loss in follicular lymphoma drives immune evasion through altered T-cell interaction

Weltermann T, Munich, Germany

 

P09.14.

Preliminary immunophenotype analysis of the systemic immune response to neoadjuvant immuno-radiotherapy in soft tissue sarcoma

Wiśniewska A, Warsaw, Poland

 

P09.15.

Genomic Landscape and Predictive Biomarkers of Primary EGFR-TKI Resistance and Long-Term Survival in Advanced EGFR-Mutant NSCLC: Implications for Immunotherapy Strategies

Yang M, Guangzhou, China

​

​

​